How to Fight Insurance Denials for Diabetes Drugs and Insulin: A Patient Guide

Thirty-eight million Americans live with diabetes, yet insurers routinely deny the very medications clinicians say you need—basal and bolus insulin analogs, GLP-1 receptor agonists like Ozempic or Mounjaro, SGLT2 inhibitors like Jardiance, insulin pump supplies, even emergency glucagon. The denials come even when your A1c is 8.4%, even when you've tried and failed older drugs, and even when landmark cardiovascular outcome trials prove the drug saves lives. Insurers lean on formulary step-therapy rules, "not medically necessary" templates, and vague policy language to push you toward older, cheaper alternatives—NPH insulin instead of Lantus, metformin alone when you need combination therapy, or generic sulfonylureas that cause severe hypoglycemia. This guide shows you how to appeal those denials using the specific clinical guidelines, trial evidence, and policy citations that actually move insurers to reverse course.

Why Insurers Deny Diabetes Drugs

Insurers use a rotating set of denial templates that look official but often ignore current evidence. Here are the five most common:

1. Step-therapy / "try generic first"

The denial says you must try (and fail) metformin, then a sulfonylurea, then a cheaper GLP-1 before approving Mounjaro—even if you're already on metformin with an A1c of 8.4% and documented sulfonylurea hypoglycemia. For insulin, they demand human NPH or Regular before covering Lantus, Levemir, or Tresiba. The insurer's medical policy lists a multi-tier ladder and declares your request "not first-line."

2. "Not medically necessary" for insulin analogs

The letter says "human insulin (NPH, Regular) is therapeutically equivalent and less costly; analog insulins (Lantus, Humalog, Novolog) are not medically necessary." This ignores ADA Standards of Care §9.5 analog preference when hypoglycemia risk is documented, when the patient is on multiple daily injections (MDI), or when glycemic variability requires tighter control.

3. SGLT2 or GLP-1 denied because "A1c at goal" or outside labeled indication

You have Type 2 diabetes with heart failure (EF 38%) or CKD stage 3b (eGFR 38) and your endocrinologist prescribed Jardiance or Ozempic for cardio-renal protection. The insurer denies it saying "A1c 7.0%, at goal; SGLT2 not indicated." This misses the entire point: SGLT2 inhibitors and GLP-1 agonists are now first-line for organ protection regardless of A1c in patients with ASCVD, heart failure, or CKD, per ADA Standards §10, KDIGO 2024, and FDA labeling updates.

4. Pump or automated insulin delivery (AID) supplies denied for "not Type 1" or "not on insulin"

Your Type 2 diabetes requires 64 units of total daily insulin via MDI (multiple daily injections ≥3/day), you've had recurrent hypoglycemia, and your endocrinologist prescribed an Omnipod 5 or Tandem t:slim X2 with Control-IQ. The insurer says "insulin pump therapy is investigational for Type 2 diabetes" or "patient does not meet Type 1 criteria." ADA §7.20 and Medicare LCD L33464 both permit pumps for insulin-requiring diabetes (Type 1 or Type 2) on MDI ≥3/day with documented need.

5. "Experimental" or "no generic available" for newer agents

Afrezza (inhaled prandial insulin) is denied as "experimental"—despite FDA approval June 27, 2014 (NDA 022472) and a decade of post-market use. Mounjaro or Zepbound denials cite "no generic GLP-1" or conflate the Type 2 diabetes indication (Mounjaro, FDA May 2022) with the obesity indication (Zepbound, FDA November 2023). Ozempic denials claim a "generic semaglutide" exists; it does not.

---

The Citations Insurers Respect

When you appeal, vague statements like "my doctor says I need this" rarely work. Insurers respond to named guidelines with year and section, pivotal trials in NEJM or Lancet, and their own medical policies read correctly. Here are the references that carry weight:

Professional society guidelines

• ADA Standards of Care in Diabetes—2025 (updated annually each January in Diabetes Care). Section 9 covers pharmacologic approaches; §9.4 and §9.5 detail when to use GLP-1, SGLT2, and insulin analogs. Section 10 addresses cardiovascular disease and chronic kidney disease management. Section 7.20 discusses insulin pump therapy criteria.
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (updated 2024). Recommends SGLT2 inhibitors for CKD patients with diabetes down to eGFR ≥20 mL/min, independent of A1c.
• ACC/AHA Heart Failure guidelines (most recent updates 2022–2023). Endorse SGLT2 inhibitors as foundational therapy in HFrEF and HFpEF, with or without diabetes.

Landmark cardiovascular and renal outcome trials (CVOTs / KOTs)

• DEVOTE (NEJM 2017): insulin degludec (Tresiba) vs. glargine U100 in Type 2 diabetes; demonstrated lower severe hypoglycemia with degludec.
• SUSTAIN-6 (NEJM 2016): semaglutide (Ozempic) reduced major adverse cardiovascular events (MACE) by 26% vs. placebo in Type 2 diabetes with ASCVD or high CV risk.
• SURPASS-1 through SURPASS-5 (NEJM 2021, Lancet 2021–2022): tirzepatide (Mounjaro) superior A1c and weight reductions vs. placebo, semaglutide, and basal insulin; SURPASS-2 head-to-head vs. semaglutide 1 mg.
• EMPA-REG OUTCOME (NEJM 2015): empagliflozin (Jardiance) cut CV death by 38% and heart failure hospitalization by 35% in Type 2 diabetes with ASCVD.
• EMPEROR-Reduced (NEJM 2020) and EMPEROR-Preserved (NEJM 2021): empagliflozin reduced heart failure outcomes in HFrEF and HFpEF, regardless of diabetes status.
• DAPA-CKD (NEJM 2020) and DAPA-HF (NEJM 2019): dapagliflozin (Farxiga) slowed CKD progression and reduced heart failure events.
• CREDENCE (NEJM 2019): canagliflozin (Invokana) reduced kidney failure risk by 30% in Type 2 diabetes with CKD.

FDA approval dates and NDA numbers (when "experimental" is alleged)

• Afrezza (inhaled insulin): FDA approved June 27, 2014, NDA 022472.
• Mounjaro (tirzepatide for Type 2 diabetes): FDA approved May 13, 2022.
• Zepbound (tirzepatide for chronic weight management): FDA approved November 8, 2023—distinct indication, same molecule.

Medicare Local Coverage Determinations (LCDs)

• LCD L33464 (Noridian, other MACs have similar): permits insulin pump therapy for any patient with diabetes requiring insulin who performs MDI (≥3 injections/day) or CSII and meets glycemic monitoring criteria; does not restrict to Type 1 only.

---

How to Argue Against Each Denial Reason

1. Fighting step-therapy / "try generic first"

The insurer's position: You must sequentially fail metformin, then a sulfonylurea (or DPP-4), then perhaps an older GLP-1, before Mounjaro or another branded agent will be covered.

Your counter-argument (concrete steps):

1. Document every prior trial. List drug, dose, duration, and outcome. Example: "Metformin 1000 mg BID × 3 years—A1c plateaued at 8.5%. Glipizide 10 mg BID × 1 year—discontinued December 2024 for three severe hypoglycemic events requiring ER visits (dates: 2024-12-03, 2024-12-18, 2025-02-10). Trulicity 0.75 mg × 6 months—A1c improved to 8.0% but discontinued due to cost/coverage issue."

2. Cite ADA Standards §9.4: For patients not at glycemic goal on metformin, combination therapy is appropriate, and the choice should be individualized based on comorbidities (ASCVD, HF, CKD), hypoglycemia risk, weight, and cost. If you have ASCVD or CKD, SGLT2 or GLP-1 is preferred next (§10.3, §10.4), not a sulfonylurea.

3. Invoke "fail-first" harm: If the formulary demands you retry a sulfonylurea after documented severe hypoglycemia, note that ADA §6.7 and §9.5 warn against agents that increase hypoglycemia risk in patients with prior severe hypo or hypoglycemia unawareness.

4. Request expedited review if your A1c is >9%, if you've had DKA, or if delays risk acute decompensation. Many states require insurers to grant exceptions when step-therapy would cause harm.

5. Attach prescriber statement: Your endocrinologist should write: "Patient has appropriately trialed and failed metformin and sulfonylurea per documentation above. Further step-therapy delays are not evidence-based and risk harm. Mounjaro is requested per ADA §9.4 and SURPASS-2 evidence."

---

2. Arguing medical necessity for insulin analogs over human insulin

The insurer's position: "NPH and Regular human insulin are therapeutically equivalent and cost-effective; analog insulins (Lantus, Humalog, Novolog, Tresiba) are not medically necessary."

Your counter-argument:

1. Cite ADA Standards §9.5: "Most people with Type 1 and many with Type 2 diabetes should be treated with basal-bolus regimens using either MDI or CSII (continuous subcutaneous insulin infusion / pump). Analog insulins are preferred due to more predictable pharmacokinetics, lower hypoglycemia risk, and flexibility."

2. Document hypoglycemia burden: If you have recurrent lows, nocturnal hypoglycemia, or hypoglycemia unawareness, note dates, glucose readings, and any ER visits or glucagon use. DEVOTE (2017) showed that degludec (Tresiba) cut severe hypo by 40% vs. glargine U100; even glargine has lower nocturnal hypo than NPH.

3. Note lifestyle and safety: If you work variable shifts, travel across time zones, are pregnant or planning pregnancy, or need flexible meal timing, analogs' flatter pharmacokinetic profiles are medically necessary. NPH's pronounced peak increases hypo risk and requires rigid meal schedules.

4. Attach endocrinology letter: "Patient is on MDI with total daily dose 64 units (Lantus 40 QHS, Humalog 8 TID). Documented hypoglycemia unawareness (GOLD score 4) and two severe hypos in past 6 months. Switching to NPH/Regular would materially increase hypoglycemia risk and worsen glycemic control, counter to ADA §9.5 and DEVOTE evidence."

---

3. Overturning SGLT2 / GLP-1 denials when "A1c at goal" or outside traditional label

The insurer's position: "A1c 7.0%, at goal; Jardiance / Ozempic not indicated for glucose lowering. CKD stage 3 does not meet threshold for SGLT2."

Your counter-argument:

1. SGLT2 and GLP-1 are now organ-protective drugs, not just glucose drugs. ADA Standards §10.3 (ASCVD), §10.4 (heart failure), and §10.5 (CKD) all say: use SGLT2 inhibitor and/or GLP-1 RA independent of A1c if the patient has:

- Established ASCVD (prior MI, stroke, PAD with ABI, coronary stenosis ≥50% on imaging).

- Heart failure with reduced ejection fraction (HFrEF) or preserved (HFpEF).

- CKD with eGFR ≥20 (KDIGO 2024 updated threshold) and albuminuria.

2. Cite the CVOTs by name:

- Jardiance (empagliflozin): EMPA-REG OUTCOME (38% reduction in CV death), EMPEROR-Reduced (HFrEF), EMPEROR-Preserved (HFpEF). FDA labeling includes heart failure indication with or without diabetes.

- Farxiga (dapagliflozin): DAPA-HF, DAPA-CKD, FDA-approved to reduce CV death and HF hospitalization in HFrEF and to slow CKD progression.

- Ozempic (semaglutide): SUSTAIN-6 (26% MACE reduction). Label includes "to reduce the risk of major adverse cardiovascular events" in T2D + ASCVD.

- Mounjaro (tirzepatide): SURPASS trials show superior A1c and weight reduction; FDA Type 2 diabetes indication May 2022.

3. KDIGO 2024: Recommends SGLT2 inhibitors for all CKD patients with diabetes and eGFR ≥20 mL/min, regardless of A1c, to slow progression to ESKD. If your eGFR is 38 and UACR 320 (stage 3b with macroalbuminuria), you are precisely the population DAPA-CKD and CREDENCE enrolled.

4. Prescriber letter template: "Patient has Type 2 diabetes with HFrEF (EF 38% per echo [date]) and CKD stage 3b (eGFR 38, UACR 320). Jardiance is prescribed for cardio-renal protection per ADA §10.4, §10.5, EMPEROR-Reduced (NEJM 2020), KDIGO 2024 recommendations, and FDA labeling (heart failure indication). A1c is irrelevant to this indication. Denial contradicts current evidence-based care."

---

4. Securing insulin pump / AID supplies when you have Type 2 diabetes or are told "not on insulin"

The insurer's position: "Insulin pump therapy is investigational for Type 2 diabetes" or "patient does not meet Type 1 diabetes criteria."

Your counter-argument:

1. Medicare LCD L33464 and ADA §7.20 do not restrict pumps to Type 1. The criteria are:

- Diabetes (Type 1 or Type 2) requiring insulin.

- Currently on MDI (≥3 injections/day) or already using CSII.

- Performing frequent self-monitoring (≥4 SMBG/day) or using CGM.

- Completed diabetes education and willing to work with pump team.

2. Document your insulin burden: "Total daily dose 64 units: Lantus 40 QHS, Humalog 8u TID with meals. MDI since [date]. Performing SMBG 6–8×/day and using Dexcom G7 CGM. Despite MDI, A1c 8.4% and frequent postprandial highs (240–280 mg/dL) and nocturnal lows (documented [dates])."

3. Explain why a pump is medically necessary for your Type 2 diabetes:

- Insulin-deficient Type 2 (C-peptide <0.6 ng/mL, if tested) functionally resembles Type 1.

- Severe insulin resistance requiring U-500 or high total daily dose.

- Recurrent hypoglycemia on MDI that hybrid closed-loop (Omnipod 5, Tandem Control-IQ, Medtronic 780G) can mitigate.

- Variable work schedule, shift work, or lifestyle factors where automated basal modulation improves safety and control.

4. Cite ADA §7.20: "Insulin pump therapy can be considered for patients with Type 1 or Type 2 diabetes requiring intensive insulin therapy who are motivated and capable of using the device."

5. Prescriber letter: "Patient has insulin-requiring Type 2 diabetes on MDI ≥3×/day, meets LCD L33464 and ADA §7.20 criteria. Automated insulin delivery (Omnipod 5) is requested to reduce glycemic variability and hypoglycemia risk. Denial based on 'not Type 1' is factually incorrect per Medicare and ADA policy."

---

5. Countering "experimental" or "no generic" claims

Afrezza (inhaled insulin) denied as experimental:

• FDA approval: June 27, 2014, NDA 022472, for adults with diabetes (Type 1 or 2) for prandial glucose control.
• Post-market use: Over a decade; listed in ADA Standards §9.5 as an ultra-rapid option for patients with needle phobia or who need discreet, rapid-onset prandial coverage.
• Prescriber statement: "Afrezza is FDA-approved, not experimental, and medically necessary for this patient who has documented needle phobia and suboptimal prandial control on injected rapid analogs."

Mounjaro / Zepbound confusion:

• Mounjaro (tirzepatide 5, 7.5, 10, 12.5, 15 mg) is FDA-approved for Type 2 diabetes (May 2022).
• Zepbound (tirzepatide 2.5, 5, 7.5, 10, 12.5, 15 mg) is FDA-approved for chronic weight management (November 2023).
• Same molecule, different indications and dosing schedules. If you have Type 2 diabetes with A1c 8.4%, your prescription is Mounjaro for diabetes treatment, not Zepbound for weight loss.
• Insurers sometimes conflate the two; clarify in your appeal: "Mounjaro is requested for FDA-approved Type 2 diabetes indication per SURPASS trials. This is not an off-label obesity request."

"Generic semaglutide" claims:

• No generic semaglutide (Ozempic, Rybelsus, Wegovy) exists as of 2026. Patents run into the 2030s.
• If denied for "generic alternative available," ask the insurer to name the NDC and manufacturer. They cannot, because it does not exist.
• If they mean liraglutide (Victoza), that is a different GLP-1 with a different efficacy profile; SUSTAIN-6 CV data is specific to semaglutide and cannot be extrapolated.

---

What We Do

We turn the clinical narrative, trial evidence, and policy citations above into a physician-ready appeal letter in under 72 hours. You upload your denial, answer our diabetes-specific intake (A1c trend, prior medications, complications, current regimen, eGFR and UACR if you have CKD, ejection fraction if you have heart failure), and our system drafts a 1.5–2 page letter citing ADA Standards of Care 2025, KDIGO 2024, the relevant CVOTs (SUSTAIN-6, SURPASS-2, EMPA-REG, EMPEROR, DAPA-CKD, DEVOTE, CREDENCE), FDA approval dates, and Medicare LCD when applicable. Your physician reviews, signs on letterhead, and submits. We do not argue your case for you—we write the medical argument so your doctor can.

---

Sources

1. American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl 1). Sections 6 (glycemic targets), 7 (technology), 9 (pharmacologic approaches), 10 (cardiovascular disease and risk management, chronic kidney disease).

2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S). Recommends SGLT2 inhibitors for CKD with diabetes, eGFR ≥20.

3. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834–1844.

4. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.

5. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med 2015;373:2117–2128.

6. Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med 2020;383:1413–1424.

7. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). N Engl J Med 2021;385:1451–1461.

8. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med 2020;383:1436–1446.

9. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med 2019;381:1995–2008.

10. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE). N Engl J Med 2019;380:2295–2306.

11. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med 2016;375:311–322.

12. Marso SP, et al. Insulin Degludec versus Insulin Glargine in Insulin-Treated Patients with Type 2 Diabetes (DEVOTE). N Engl J Med 2017;377:723–732.

13. U.S. Food and Drug Administration. Afrezza (insulin human) Inhalation Powder—Approval Letter, NDA 022472, June 27, 2014.

14. U.S. Food and Drug Administration. Mounjaro (tirzepatide)—Approval Letter, May 13, 2022 (Type 2 diabetes indication).

15. Centers for Medicare & Medicaid Services, Noridian Healthcare Solutions. Local Coverage Determination (LCD): Insulin Infusion Pump (L33464). Revised 2023. Criteria permit pump therapy for insulin-requiring diabetes (Type 1 or Type 2) on MDI ≥3 injections/day.

16. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2022;79(17):e263–e421. Recommends SGLT2 inhibitors as foundational therapy in HFrEF and beneficial in HFpEF.

17. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2024. 38.4 million Americans (11.6% of population) have diabetes.

18. Gaffney A, et al. Prevalence and Correlates of Patient Rationing of Insulin in the United States. Ann Intern Med 2022;175(11). Found approximately 1.3 million insulin users reported cost-related underuse.